Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
David M. Schuster, MD
With
National Cancer Institute (NCI)
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
STUDY NOW CLOSED for recruitment
Patients must be 18 years of age or older.
Patients will have been originally diagnosed with localized (Stage T1c, T2, or T3 ) prostate carcinoma and have undergone what was considered definitive therapy for localized disease.
In the case of brachytherapy, cryotherapy, or external beam radiation, treatment will have occurred at least 2 years in the past to eliminate patients with so-called "PSA bump."
Patient will have suspicion of recurrent prostate carcinoma as defined by: ASTRO criteria of three consecutive rises of PSA or earlier if clinically appropriate, and/or nadir + 2.0 after radiotherapy, and/or greater than 0.3 after prostatectomy.
Ability to lie still for PET scanning
Patients must be able to provide written informed consent.
You may not be if
Age less than 18.
Greater than T3 disease in past
Prior prostatectomy or 2 years since brachytherapy, cryotherapy, or external beam radiation therapy.
Does not meet above criteria of suspicious PSA elevation
Inability to lie still for PET scanning
Cannot provide written informed consent.
Bone scan findings characteristic for metastatic prostate carcinoma
Less than 2 months since any prior prostate biopsy (to decrease false positive uptake from inflammation).
Clareo Health | FACBC PET/CT for Recurrent Prostate Cancer
